CA-IMPERVA
3.11.2022 13:02:06 CET | Business Wire | Press release
Imperva, Inc., (@Imperva) the cybersecurity leader whose mission is to help organizations protect their data and all paths to it, releases The State of Security Within eCommerce 2022 report, a 12-month analysis by Imperva Threat Research of cybersecurity threats targeting the retail industry. A range of automated threats -- from account takeover, credit card fraud, web scraping, API abuses, Grinch bots, and distributed denial of service (DDoS) attacks -- were a persistent challenge for the eCommerce industry, threatening online sales and customer satisfaction. The continued barrage of attacks on retailers’ websites, applications, and APIs throughout the calendar year, and during the peak holiday shopping season, is a continued business risk for the retail industry.
“The holiday shopping season is a critical period for the retail industry, and security threats could undermine retailers’ bottom line again in 2022,” says Lynn Marks, Senior Product Manager, Imperva. “This industry faces a variety of security risks, the majority of which are automated and operate around the clock. Retailers need a unified approach to stop these persistent attacks, one that focuses on the protection of data and is equipped to mitigate attacks quickly without disrupting shoppers.”
An Automated Adversary: Bad Bots & Online Fraud Plague Retail Sites
In the past 12 months, nearly 40% of traffic on retailers’ websites didn’t come from a human. Instead, it came from a bot, software applications controlled by operators that run automated tasks, often with malicious intent. In the retail industry, the infamous Grinch bot is notorious for inventory hoarding during the holiday shopping season, scooping up high-demand items and making it challenging for consumers to purchase gifts online.
Some of the key trends monitored by Imperva include:
- Of all the traffic on retailers’ websites, nearly one-quarter (23.7%) was attributed specifically to bad bots, malicious automation that contributes to online fraud. The proportion of advanced bots -- scripts that use the latest evasion techniques to mimic human behavior and avoid detection -- on retail sites grew over the prior year (from 23.4% to 31.1%). Advanced bots are a considerable challenge for organizations to stop without the right defenses in place.
- In 2021, bot-related attacks on retail sites grew 10% in October and grew another 34% in November, suggesting that bot operators increase their nefarious efforts around peak holiday shopping periods.
- Account takeover (ATO) is another form of online fraud in which cybercriminals attempt to compromise online accounts by using stolen passwords and usernames. In 2021, 64.1% of ATO attacks used an advanced bad bot. Of all login attempts on retail websites, 22.6% were malicious, nearly twice the volume that was recorded on sites across other industries. Attackers used leaked credentials 94.7% of the time in credential stuffing attacks targeting retailers, compared to 69.6% of the time in other industries.
API Abuses and Attacks Multiply, Creating New Challenges for Retailers
APIs are the invisible connective tissue that enable applications to share data and invoke digital services. Analysis by Imperva Threat Research finds that traffic from an API accounts for 41.6% of all traffic to online retailers’ sites and applications. Of that, 12% of traffic directs to endpoints, like a database, where personal data is stored (e.g. credentials, identification numbers, etc.). More concerning, 3 - 5% of API traffic is directed to undocumented or Shadow APIs, endpoints that security teams don’t know exist or no longer protect.
Exposed or vulnerable APIs are a considerable threat for retailers because attackers can use the API as a pathway for exfiltrating customer data and payment information. API abuses are often carried out through automated attacks where a botnet floods the API with unwanted traffic, seeking vulnerable applications and unprotected data. In 2021, API attacks increased by 35% between September and October, and then spiked another 22% in November on top of the previous months’ elevated attack levels. This finding suggests that bad actors scale their efforts around the holiday shopping season as more data is exchanged between the APIs and applications that power eCommerce services.
Beware of Downtime: DDoS Attacks Continue to Threaten Retailers
A distributed denial of service (DDoS) attack is an automated threat that attempts to disrupt critical business operations by flooding the network or application infrastructure with malicious traffic. The attacks are often launched by a botnet, a group of compromised connected devices that are distributed across the Internet and operated by a single party.
Imperva Threat Research finds that DDoS attacks in 2022 are larger and stronger across all industries. The number of incidents recorded that were greater than 100 Gbps doubled, and attacks larger than 500 Gbps/0.5 Tbps increased 287%. What’s more, those targeted by an attack are often attacked again within 24 hours. In fact, 55% of websites hit by an application layer DDoS and 80% hit by a network layer DDoS were attacked multiple times.
A DDoS attack is a nonstop threat for retailers. The downtime caused by a DDoS attack can lead to site disruption, reputational damage, and revenue loss. A DDoS is a critical threat to online retailers that rely on application performance and availability to enable digital storefronts.
Additional Information:
- Download the The State of Security Within e-Commerce 2022 report
- Learn how Imperva products and solutions help retailers protect their applications, APIs, and data from security risks.
- See how bad bots create business disruption across different industries.
- Check out the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.
About Imperva:
Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.
© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
